[go: up one dir, main page]

WO2018154118A3 - Aromatic compounds which enhance notch signaling, for use in therapy - Google Patents

Aromatic compounds which enhance notch signaling, for use in therapy Download PDF

Info

Publication number
WO2018154118A3
WO2018154118A3 PCT/EP2018/054686 EP2018054686W WO2018154118A3 WO 2018154118 A3 WO2018154118 A3 WO 2018154118A3 EP 2018054686 W EP2018054686 W EP 2018054686W WO 2018154118 A3 WO2018154118 A3 WO 2018154118A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
aromatic compounds
notch signaling
disorders
enhance notch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2018/054686
Other languages
French (fr)
Other versions
WO2018154118A2 (en
Inventor
Viktoria REINMÜLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xeniopro GmbH Germany
Original Assignee
Xeniopro GmbH Germany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeniopro GmbH Germany filed Critical Xeniopro GmbH Germany
Priority to JP2019543962A priority Critical patent/JP7282036B2/en
Priority to AU2018223177A priority patent/AU2018223177B2/en
Priority to EP18709290.3A priority patent/EP3585485A2/en
Priority to US16/488,458 priority patent/US11591289B2/en
Publication of WO2018154118A2 publication Critical patent/WO2018154118A2/en
Publication of WO2018154118A3 publication Critical patent/WO2018154118A3/en
Anticipated expiration legal-status Critical
Priority to US18/064,576 priority patent/US20230406814A2/en
Priority to AU2024205480A priority patent/AU2024205480A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the hematopoietic system including the hematologic system in human and veterinary medicine.
PCT/EP2018/054686 2017-02-24 2018-02-26 Novel aromatic compounds Ceased WO2018154118A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2019543962A JP7282036B2 (en) 2017-02-24 2018-02-26 novel aromatic compounds
AU2018223177A AU2018223177B2 (en) 2017-02-24 2018-02-26 Aromatic compounds which enhance notch signaling, for use in therapy
EP18709290.3A EP3585485A2 (en) 2017-02-24 2018-02-26 Aromatic compounds which enhance notch signaling, for use in therapy
US16/488,458 US11591289B2 (en) 2017-02-24 2018-02-26 Aromatic compounds
US18/064,576 US20230406814A2 (en) 2017-02-24 2022-12-12 Novel aromatic compounds
AU2024205480A AU2024205480A1 (en) 2017-02-24 2024-08-02 Novel aromatic compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762463212P 2017-02-24 2017-02-24
US62/463,212 2017-02-24
EP17160326 2017-03-10
EP17160326.9 2017-03-10
EP17205950 2017-12-07
EP17205950.3 2017-12-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/488,458 A-371-Of-International US11591289B2 (en) 2017-02-24 2018-02-26 Aromatic compounds
US18/064,576 Division US20230406814A2 (en) 2017-02-24 2022-12-12 Novel aromatic compounds

Publications (2)

Publication Number Publication Date
WO2018154118A2 WO2018154118A2 (en) 2018-08-30
WO2018154118A3 true WO2018154118A3 (en) 2018-12-06

Family

ID=63253169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/054686 Ceased WO2018154118A2 (en) 2017-02-24 2018-02-26 Novel aromatic compounds

Country Status (1)

Country Link
WO (1) WO2018154118A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
AU2019325306A1 (en) * 2018-08-24 2021-02-18 Xeniopro GmbH Phenoxy(hetero)aryl ethers of antiproliferative activity
SG11202101093QA (en) * 2018-08-24 2021-04-29 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
AU2020241258B2 (en) 2019-03-15 2025-09-11 The General Hospital Corporation Novel small molecule inhibitors of TEAD transcription factors
CA3156303A1 (en) * 2019-10-03 2021-04-08 Tenaya Therapeutics, Inc. 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES
JP2023508907A (en) 2019-12-20 2023-03-06 テナヤ セラピューティクス， インコーポレイテッド Fluoroalkyl-oxadiazoles and uses thereof
JP2024519499A (en) 2021-05-04 2024-05-14 テナヤ セラピューティクス， インコーポレイテッド 2-Fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazoles, HDAC6 inhibitors for use in the treatment of metabolic disorders and HFPEF - Patent Application 20070123333

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2754286A (en) * 1951-10-15 1956-07-10 Du Pont Aldehydes and their acetals
US3113849A (en) * 1960-06-23 1963-12-10 Dow Chemical Co Solid gels of liquid hydrocarbons containing salts of alkylphenoxybenzoic acids
US3940403A (en) * 1972-05-15 1976-02-24 Shionogi & Co., Ltd. Substituted acetic acid derivatives and production thereof
WO1993003012A1 (en) * 1991-08-02 1993-02-18 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
WO1993024442A1 (en) * 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
EP1145718A1 (en) * 1999-01-22 2001-10-17 Institute of Medicinal Molecular Design, Inc. DICARBA-closo-DODECABORANE DERIVATIVES
GB2380193A (en) * 2001-10-01 2003-04-02 Syngenta Ltd Crocacin analogue fungicides
EP1710233A1 (en) * 2004-01-28 2006-10-11 Kissei Pharmaceutical Co., Ltd. Novel benzofuran derivative, medicinal composition containing the same, and uses of these
WO2007022371A2 (en) * 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
JP2011001294A (en) * 2009-06-18 2011-01-06 Sumitomo Chemical Co Ltd Amide compound and application thereof for controlling plant disease
WO2013093885A1 (en) * 2011-12-21 2013-06-27 Ecole polytechnique fédérale de Lausanne (EPFL) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
WO2017158190A1 (en) * 2016-03-17 2017-09-21 Ecole polytechnique fédérale de Lausanne (EPFL) Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch
WO2018096510A1 (en) * 2016-11-28 2018-05-31 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2754286A (en) * 1951-10-15 1956-07-10 Du Pont Aldehydes and their acetals
US3113849A (en) * 1960-06-23 1963-12-10 Dow Chemical Co Solid gels of liquid hydrocarbons containing salts of alkylphenoxybenzoic acids
US3940403A (en) * 1972-05-15 1976-02-24 Shionogi & Co., Ltd. Substituted acetic acid derivatives and production thereof
WO1993003012A1 (en) * 1991-08-02 1993-02-18 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
WO1993024442A1 (en) * 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
EP1145718A1 (en) * 1999-01-22 2001-10-17 Institute of Medicinal Molecular Design, Inc. DICARBA-closo-DODECABORANE DERIVATIVES
GB2380193A (en) * 2001-10-01 2003-04-02 Syngenta Ltd Crocacin analogue fungicides
EP1710233A1 (en) * 2004-01-28 2006-10-11 Kissei Pharmaceutical Co., Ltd. Novel benzofuran derivative, medicinal composition containing the same, and uses of these
WO2007022371A2 (en) * 2005-08-16 2007-02-22 Genzyme Corporation Chemokine receptor binding compounds
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
JP2011001294A (en) * 2009-06-18 2011-01-06 Sumitomo Chemical Co Ltd Amide compound and application thereof for controlling plant disease
WO2013093885A1 (en) * 2011-12-21 2013-06-27 Ecole polytechnique fédérale de Lausanne (EPFL) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
WO2017158190A1 (en) * 2016-03-17 2017-09-21 Ecole polytechnique fédérale de Lausanne (EPFL) Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch
WO2018096510A1 (en) * 2016-11-28 2018-05-31 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
AIYING GUAN ET AL: "Design, Synthesis, and Structure-Activity Relationship of New Pyrimidinamine Derivatives Containing an Aryloxy Pyridine Moiety", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 65, no. 6, 6 February 2017 (2017-02-06), US, pages 1272 - 1280, XP055485673, ISSN: 0021-8561, DOI: 10.1021/acs.jafc.6b05580 *
BUCK E ET AL: "Ullmann diaryl ether synthesis: rate aceleration by 2,2,6,6-tetramethylheptane-3,5-dione", ORGANIC LETTERS , 14(23), 6012-6015 CODEN: ORLEF7; ISSN: 1523-7052,, vol. 4, no. 9, 1 January 2002 (2002-01-01), pages 1623 - 1626, XP002403679, ISSN: 1523-7060, DOI: 10.1021/OL025839T *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 February 2009 (2009-02-01), XP002782255, accession no. 1099130-61-6 Database accession no. 1099130-61-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1 February 2009 (2009-02-01), XP002782261, accession no. 1098368-66-1 Database accession no. 1098368-66-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 May 2008 (2008-05-15), XP002782250, accession no. 1020936-29-1 Database accession no. 1020936-29-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 15 November 2007 (2007-11-15), XP002782259, accession no. 953720-22-4 Database accession no. 953720-22-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 August 2008 (2008-08-17), XP002782253, accession no. 1041517-52-5 Database accession no. 1041517-52-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 November 2007 (2007-11-19), XP002782260, accession no. 954564-77-3 Database accession no. 954564-77-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 February 2014 (2014-02-20), XP002782256, accession no. 1550449-98-3 Database accession no. 1550449-98-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 February 2014 (2014-02-20), XP002782265, accession no. 1550451-20-1 Database accession no. 1550451-20-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 June 2016 (2016-06-22), XP002782258, accession no. 1937165-19-9 Database accession no. 1937165-19-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 July 2016 (2016-07-25), XP002782268, accession no. 1958884-22-4 Database accession no. 1958884-22-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 May 2016 (2016-05-25), XP002782266, accession no. 1917642-56-8 Database accession no. 1917642-56-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 November 2013 (2013-11-25), XP002782254, accession no. 1480752-41-7 Database accession no. 1480752-41-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 July 2008 (2008-07-27), XP002782251, accession no. 1036524-79-4 Database accession no. 1036524-79-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 28 July 2008 (2008-07-28), XP002782252, accession no. 1036598-46-5 Database accession no. 1036598-46-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 29 December 2013 (2013-12-29), XP002782264, accession no. 1506498-75-4 Database accession no. 1506498-75-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 29 July 2016 (2016-07-29), XP002782269, accession no. 1962787-08-1 Database accession no. 1962787-08-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 July 2016 (2016-07-03), XP002782267, accession no. 1944481-23-5 Database accession no. 1944481-23-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 November 2013 (2013-11-04), XP002782262, accession no. 1468989-97-0 Database accession no. 1468989-97-0 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 December 2012 (2012-12-05), XP002782257, accession no. 1411168-77-8 Database accession no. 1411168-77-8 *
FENG LI ET AL: "Synthesis of Diaryl Ethers, Diaryl Sulfides, Heteroaryl Ethers and Heteroaryl Sulfides under Microwave Dielectric Heating", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, no. 8, 19 April 2005 (2005-04-19), pages 1305 - 1313, XP002435109, ISSN: 0039-7881, DOI: 10.1055/S-2005-865321 *
GENZO ITO ET AL: "Notiz uber einige neue Diphenylather-aldehyde und deren Thiosemicarbazone.", PHARMACEUTICAL BULLETIN, vol. 5, no. 6, 1 January 1957 (1957-01-01), pages 619 - 621, XP055486381, ISSN: 0369-9471, DOI: 10.1248/cpb1953.5.619 *
JIN HOU ET AL: "Evaluation of Novel N -(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells", CHEMICAL BIOLOGY & DRUG DESIGN., vol. 86, no. 2, 1 August 2015 (2015-08-01), GB, pages 223 - 231, XP055485858, ISSN: 1747-0277, DOI: 10.1111/cbdd.12484 *
MARTA P CARRASCO ET AL: "Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites", CHEMMEDCHEM, 6 October 2016 (2016-10-06), Germany, pages 2194 - 2204, XP055514603, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002/cmdc.201600327&file=cmdc201600327-sup-0001-misc_information.pdf> DOI: 10.1002/cmdc.201600327 *
MARTA P. CARRASCO ET AL: "Probing the aurone scaffold against Plasmodium falciparum: Design, synthesis and antimalarial activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 80, 1 June 2014 (2014-06-01), FR, pages 523 - 534, XP055513880, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2014.04.076 *
MARTA P. CARRASCO ET AL: "Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites", CHEMMEDCHEM, vol. 11, no. 19, 19 August 2016 (2016-08-19), DE, pages 2194 - 2204, XP055513882, ISSN: 1860-7179, DOI: 10.1002/cmdc.201600327 *
P. M. HERGENROTHER ET AL: "Synthesis and thermal reaction of 2-[4-(4-ethynylphenoxy)phenylene]-3-phenylquinoxaline", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 13, no. 5, 1 October 1976 (1976-10-01), US, pages 993 - 999, XP055485851, ISSN: 0022-152X, DOI: 10.1002/jhet.5570130512 *
V A ; GIORDANO ET AL: "Effect of Chain Length on Mesomorphfsm of Steroid Esters of 4-(4-Alkylphenyl-X)benzoic Acids with X = CO, 0, S, and CH2", JOURNAL OF PHYSICAL CHEMISTRY, 1 January 1973 (1973-01-01), pages 4730 - 4737, XP055470685, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/j100246a037> *
YABUNAKA H ET AL: "Hybrid ubiquinone: novel inhibitor of mitochondrial complex I", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGET, AMSTERDAM, NL, vol. 1556, no. 2-3, 2 December 2002 (2002-12-02), pages 106 - 112, XP004396758, ISSN: 0005-2728, DOI: 10.1016/S0005-2728(02)00341-9 *

Also Published As

Publication number Publication date
WO2018154118A2 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
WO2018154118A3 (en) Aromatic compounds which enhance notch signaling, for use in therapy
WO2018033254A3 (en) Rna for cancer therapy
WO2016025635A3 (en) Combination therapy for treating cancer
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
MX2023014569A (en) Anti-sirp alpha antibodies.
MX2020001513A (en) Clec9a binding agents and use thereof.
PH12018502429A1 (en) Antibody molecules for cancer treatment
WO2020039088A3 (en) Aromatic molecules for use in the treatment of pathological conditions
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
WO2016043874A3 (en) Combination therapy for treating cancer
SG10201902664RA (en) Combination therapy for treating cancer
EA201590654A1 (en) COMBINATION OF RASAGILIN AND PRIDOPIDINE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF HANTINGTON&#39;S DISEASE
EP4140487A8 (en) Combination therapy for treating cancer
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
MA49339A (en) Oligomer extended insulin-fc conjugates
MX2019004280A (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine.
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
MX2018002223A (en) Novel insulin derivatives and the medical uses hereof.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
PH12021550872A1 (en) Therapeutic compounds
EP3581175A4 (en) MEDICINAL DELIVERY FORMULATION FOR THE TREATMENT OF MENTAL DISEASES OR CENTRAL NERVOUS SYSTEM DISORDERS
MX379359B (en) DERIVATIVES OF 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECane.
MX379201B (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX376473B (en) COMPOSITION FOR TREATING BRAIN INJURIES.
MX2023010711A (en) Phenalkylamines and methods of making and using the same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18709290

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019543962

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018223177

Country of ref document: AU

Date of ref document: 20180226

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018709290

Country of ref document: EP

Effective date: 20190924